Sebastian Zeissig  © ECCO

Dear ECCO Friends and Members,

It is with great pleasure and excitement that we announce the brand new ECCO Young Researcher Award 2022. This new ECCO Prize will be awarded to outstanding young researchers in recognition of their excellent contributions to basic and clinical science in the field of IBD. With this prize, ECCO strives to further support the visibility of exceptional young talents in IBD, acknowledge their achievements in the field and facilitate their ongoing and future research.

IBD Intensive Course for Trainees © ECCO

The 21^st ECCO Intensive Course for Trainees designed for residents, fellows in gastroenterology and junior faculty will take place in Copenhagen, Denmark, on March 1, 2022, immediately prior to our next Congress. We are pleased to inform you that the preliminary programme for this course is already available.

N-ECCO School © ECCO

At the 18^th Congress of ECCO in Copenhagen, the Nurses of ECCO (N-ECCO) will host the educational activity for IBD Nurses, N-ECCO School, for the 14^th time. ECCO intends to give nurses, who might be still in training and have an interest in IBD, the possibility to attend an IBD-focused course. The ultimate aim of this programme is to improve nurse education throughout Europe.

To submit an abstract for the 18^th Congress of ECCO, use our ECCO Portal.

Please also view important information on the submission process and the guidelines for abstract submission.

Alessandro Armuzzi © Alessandro Armuzzi

Brigida Barberio © Brigida Barberio

Spyros Siakavellas © Spyros Siakavellas

Dear IBD colleagues and friends,

Warm greetings from the ECCO News Team at the beginning of this hopeful spring, following two very challenging years.

After two years of meeting each other virtually due to the COVID-19 pandemic, we are optimistic that next year we will return to face-to-face interaction at the 18th Congress of ECCO in the vibrant city of Copenhagen. At last, we will able to share and exchange knowledge and ideas in person and not from behind a screen!

Scientific sessions will be held from Thursday to Saturday, March 2–4, 2023, while the Educational Programme will start earlier in the week, on Wednesday, March 1, and will finish at the end of the morning of March 2 in order to allow for a seamless experience with no overlapping sessions and to cater for all delegates. We kindly ask you to take a careful look at the ECCO'23 Congress Website for further details.

In a recent randomized trial by Ytterberg and colleagues, called Oral Surveillance, patients with rheumatoid arthritis (RA) aged > 50 years and with at least an additional cardiovascular (CV) risk factor at baseline, treated with tofacitinib 5 or 10 mg twice daily experienced a higher proportion of major adverse cardiovascular events (MACE) and cancer compared with the control group (adalimumab or etanercept) [1]. 

These new data might have crucial implications in ulcerative colitis (UC) where tofacitinib, filgotinib and upadacitinib are approved.

Laurent Peyrin-Biroulet © ECCO

Dear ECCO Friends,

With the summer approaching we hope you enjoy the second Issue of ECCO NEWS where you will find the preliminary scientific programme and our educational Activities at ECCO’23. As usual we offer a wide range of Workshops and Courses for IBD Nurses, surgeons, young gastroenterologists, paediatricians, scientists and allied healthcare professionals.

Presented by:
Axel Dignass, MD, PhD – Frankfurt, Germany
Iris Dotan, MD – Petah Tikva, Israel
James Lindsay, PhD, BM BCh, FRCP – London, UK

Conventional therapies remain the most common first-line treatments for moderate to severe ulcerative colitis (UC) in the EU, including aminosalicylates (5-ASAs), corticosteroids, and immunosuppresants.¹ However, clinical remission is not always achieved with conventional therapies in certain patient populations.² According to one retrospective study of patient-reported outcomes of 256 patients, more than half of patients did not achieve control of clinical measures, such as rectal bleeding or normal stool frequency, with the use of conventional therapies.²

Diet is a significant factor in the development of Inflammatory Bowel Disease (IBD) and management of the condition. The Crohn’s Disease Exclusion Diet (CDED) has been shown to be effective in achieving remission, but could it be used more widely?

Increased fibre intake is a key element of CDED, but does it always have a beneficial impact? Recent studies have investigated how CDED impacts the microbiota and whether food additives could contribute to the development of IBD.

jkghjhkljhjkhhlöjkhkljkljlklklklklklkknkjnjknknnkjnklnknknmmmmmmmmmmmmmmmmmmmmmmm

This interactive event brought together leading experts to explore the value of holistic, multidisciplinary care for patients with Inflammatory Bowel Disease (IBD) and discuss the use of the preferential Janus kinase 1 (JAK1) inhibitor Jyseleca^®▼ (filgotinib) for moderate to severe Ulcerative Colitis (UC). Built to be audience led, attendees voted for the data and perspectives they most wanted to hear.

This exciting session showcases:

• Nine expert faculty
• Two real-world case examples
• Audience-guided content
• Practice-focussed discussion